Literature DB >> 22529702

Rifaximin for the prevention of spontaneous bacterial peritonitis.

Georgios N Kalambokis, Athanasia Mouzaki, Maria Rodi, Epameinondas V Tsianos.   

Abstract

According to a review article by Biecker et al published in a previous issue of World Journal of Gastroenterology in March 2011, intestinal decontamination with norfloxacin remains the mainstay of primary prophylaxis of spontaneous bacterial peritonitis (SBP) at the expense of development of quinolone-resistant bacteria after long-term use. In our research, the administration of a 4-wk regimen with rifaximin 1200 mg/d reduced significantly the ascitic neutrophil count in cirrhotic patients with sterile ascites in line with a significant decrease in plasma endotoxin levels. Our observations concur with recent findings, showing a significantly reduced 5-year probability of SBP in cirrhotic patients taking rifaximin.

Entities:  

Keywords:  Ascites; Cirrhosis; Rifaximin; Spontaneous bacterial peritonitis

Mesh:

Year:  2012        PMID: 22529702      PMCID: PMC3325539          DOI: 10.3748/wjg.v18.i14.1700

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  5 in total

1.  Tumor necrosis factor-alpha, interleukin-6, and nitric oxide in sterile ascitic fluid and serum from patients with cirrhosis who subsequently develop ascitic fluid infection.

Authors:  J Such; D J Hillebrand; C Guarner; L Berk; P Zapater; J Westengard; C Peralta; G Soriano; J Pappas; B A Runyon
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

2.  Diagnosis and therapy of ascites in liver cirrhosis.

Authors:  Erwin Biecker
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

3.  Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis.

Authors:  J Vlachogiannakos; A S Saveriadis; N Viazis; I Theodoropoulos; K Foudoulis; S Manolakopoulos; S Raptis; D G Karamanolis
Journal:  Aliment Pharmacol Ther       Date:  2009-02-07       Impact factor: 8.171

Review 4.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

5.  Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.

Authors:  Jiannis Vlachogiannakos; Nikos Viazis; Panagiota Vasianopoulou; Irene Vafiadis; Dimitrios G Karamanolis; Spiros D Ladas
Journal:  J Gastroenterol Hepatol       Date:  2013-03       Impact factor: 4.029

  5 in total
  7 in total

Review 1.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Multi-resistant bacteria in spontaneous bacterial peritonitis: a new step in management?

Authors:  Angelo Alves de Mattos; Ane Micheli Costabeber; Livia Caprara Lionço; Cristiane Valle Tovo
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Rifaximin Improves Spatial Learning and Memory Impairment in Rats with Liver Damage-Associated Neuroinflammation.

Authors:  Paola Leone; Gergana Mincheva; Tiziano Balzano; Michele Malaguarnera; Vicente Felipo; Marta Llansola
Journal:  Biomedicines       Date:  2022-05-28

Review 4.  Regulation of wound healing and organ fibrosis by toll-like receptors.

Authors:  Peter Huebener; Robert F Schwabe
Journal:  Biochim Biophys Acta       Date:  2012-12-04

Review 5.  Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step.

Authors:  Hiroshi Fukui
Journal:  J Clin Transl Hepatol       Date:  2017-06-29

6.  The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial.

Authors:  Nina Kimer; Mads Meldgaard; Ole Hamberg; Thit Mynster Kronborg; Allan M Lund; Holger Jon Møller; Flemming Bendtsen; Henriette Ytting
Journal:  PLoS One       Date:  2022-03-14       Impact factor: 3.240

7.  Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.

Authors:  M Assem; M Elsabaawy; M Abdelrashed; S Elemam; S Khodeer; W Hamed; A Abdelaziz; G El-Azab
Journal:  Hepatol Int       Date:  2015-12-10       Impact factor: 9.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.